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DCD and AKI Allografts Offer a Valuable Platform to 
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Objective: To test the hypothesis that gene expression profiling in peripheral blood from patients who 
have undergone renal transplantation will provide mechanistic insights regarding graft repair and 
regeneration.    
 
Background: The source (and therefore functional status) of kidneys donated for transplantation varies 
widely. Traditionally, grafts obtained from a living donor (LD) function well immediately following 
transplantation whereas organs that experience acute damage, e.g. from donation after cardiac death 
(DCD) or acute kidney injury (AKI) donors, may experience a period of delayed function – after which 
they function as well as LD kidneys. Our goal is to provide a more complete understanding of the 
molecular basis for this recovery as it is occurring in the graft recipient within the first 30 days post-
transplant.     
 
Methods: Peripheral blood was collected from patients prior to surgery, immediately after (for up to 5 
consecutive days), twice weekly for the next 3 weeks, and at post-surgery day 28-30 following kidney 
transplantation (KT) with LD, DCD or AKI donor grafts. Total RNA was isolated from patient samples 
(representing from 4-9 time points per patient) and assayed on whole genome microarrays. Longitudinal 
gene expression analysis was performed to identify molecular pathways and processes involved in the 
recovery phase following KT.  
 
Results: Comparison of longitudinal gene expression between LD and AKI/DCD samples revealed two 
clusters, representing 141 differentially expressed transcripts. A subset of 11 transcripts was found to be 
differentially expressed in both AKI and DCD samples compared to LD. In all KT patients, regardless 
of donor graft source, the most robust gene expression changes were observed in the day immediately 
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following KT, with a coordinate upregulation of innate inflammatory response pathways (e.g. IL-6, IL-
8, IL-17A, and nitric oxide signaling). Beyond day 1, gene expression profiles differed depending upon 
the source of the graft. In patients receiving LD grafts, the expression of most genes did not remain 
highly elevated beyond the first day post-transplantation, while in the other two groups much of the 
elevation in gene expression was maintained for at least 5 days following surgery. In all cases, the 
pattern of coordinate gene over-expression had ceased by days 28-30.   
 
Conclusions: Following kidney transplantation, gene expression in peripheral blood is significantly 
different in patients receiving LD versus AKI or DCD grafts, with 11 transcripts showing differential 
expression, over time, in both AKI and DCD recipients compared to LD. Moreover, the pattern of gene 
expression in the peripheral blood of KT patients is different, depending upon the source of donor graft. 
These markedly different expression patterns, particularly the coordinate elevation hundreds of 
expressed genes in DCD and AKI recipients beyond post-transplant day 1, provide further insight into 
potential mechanisms and timing of kidney recovery (i.e. repair and regeneration) that occurs following 
kidney transplantation.  
 
 
Keywords: renal transplantation, gene expression, peripheral blood, biomarkers, regeneration and repair 
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As the demand for transplantable kidneys far exceeds the available supply [1], it has long been a 
clinical imperative to the transplant community to develop strategies that increase the number of 
transplantable organs or, more recently, reduce the demand by preventing progression to end stage organ 
failure requiring replacement therapy [2, 3]. And while kidney donation from a living donor (LD) still 
represents the gold standard in kidney transplantation (KT), the usable donor organ pool goes well 
beyond this resource (www.unos.org, [4]). Among the different categories of renal allografts, kidneys 
that have experienced acute damage before or during procurement (e.g. acute kidney injury (AKI) renal 
allografts and donation after cardiac death (DCD)), represent valuable organ sources for KT since the 
allograft will typically recover and resume normal function in the new host within the initial few weeks 
post-transplant [5-12].  
As the mechanisms that underlie adaptive repair in the kidney are still largely unknown [13], we 
suggest that monitoring DCD and AKI renal allograft recovery in the transplant recipient represents a 
truly unique platform to study this phenomenon. In fact, due to the very nature of DCD and AKI 
(DCD/AKI) organ donation, the majority of DCD/AKI allograft recipients will experience delayed graft 
function (DGF) - which is a form of acute injury unique to the transplant process - but will eventually 
resume a normal function if donors and recipients are judiciously matched[5, 11]. Very importantly, 
given that DGF occurs in a tightly controlled scenario where the sequence of events and the evolution of 
the underlying biological phenomena can be closely monitored, the study of gene expression changes in 
DCD/AKI allograft recipients provides a highly relevant in-human model to investigate how the kidney 
repairs and regenerates after injury. 
The genome-wide study of temporal variations in gene expression[14] is being widely used in 
modern medicine to better understand the molecular control of biological processes[15]. Importantly, 
this approached has been applied to transplant medicine and in particular to kidney transplantation, in 
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the attempt to better understand the pathophysiology of phenomena like acute rejection[16-20], chronic 
allograft injury[21], tolerance[22-24] and graft loss[25-27] through the identification of the 
consequences of static and dynamic genomic variation on allograft outcomes[15]. In this pilot study, we 
have used a functional genomics approach to investigate changes in peripheral blood gene expression 
that occur in the days following kidney transplantation. Two groups of patients were examined: (1) those 
who received a kidney from a related or unrelated living donor and, (2) those who received a kidney 
from a DCD or AKI donor – both of which, as mentioned above, are grafts that typically experience a 
transitory delay prior to optimal functioning in the new host. 
This study was conceived, designed and performed to test the hypothesis that non-invasive, gene 
expression-based monitoring of peripheral blood following renal transplantation will provide novel 




Between May 2014 and July 2015 a total of 110 patients preparing to undergo KT at the 
Abdominal Organ Transplant Center at Wake Forest Baptist Hospital (representing all types of donor 
grafts: e.g. LD, DCD, AKI, standard criteria donor (SCD) and donation after brain death (DBD)) were 
recruited into our IRB-approved study (IRB00027118). From these, 16 patients (5 each from those 
receiving LD or AKI and 5 receiving DCD grafts) were chosen for this pilot study. Table 1 reports 
essential information on each patient and corresponding donor. Fifteen of the sixteen patients were 
induced with alemtuzumab 30 mg IV, administered throughout 3 hours during surgery. One patient 
received basiliximab 20 mg IV, at time 0 and day 4. All patients received a maintenance regimen based 
on tacrolimus (targeting 8-10 ng/ml during the first three months), mycophenolic acid (360 mg BID for 
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patients older than 60 years of age, 720 mg BID for younger patients) and prednisone taper. However, 
sensitized patients as well as patients whose baseline kidney disease was immune-mediated, were kept 
on prednisone long term. Data gathered for each consented patient included demographic information 
and a complete medical history, as well as medication usage, pre- and post-transplant clinical laboratory 
results, and results from outcomes monitoring. Banked biospecimens include peripheral blood samples 
collected pre-transplant (Day 0) and at up to 11 additional times throughout post-transplant Day 1-30 
(Figure 1).  The study follow up ended at one month because, in our experience, the chances to resume a 
decent function (corresponding to a GFR >30 ml/min) for a DGF kidney that, at this time point, still 
shows a poor function (GFR <20 ml/min), are basically null.     
KT patients within our clinic are monitored closely in the initial 30 days following surgery as 
part of the routine standard of care. Blood is drawn from the graft recipient at admission (day 0), daily 
until discharge, and then twice weekly up to day 30, for a total of up to 12 blood samplings per patient 
(Figure 1). For patients who had consented to participate in this study, each time a clinically indicated 
blood draw was scheduled, an additional blood sample (2.5 ml) was collected, transferred into a 
PAXgene Blood RNA tube (Qiagen; Valencia, CA) and stored at -20oC for later processing. Multiple 
blood samples (4-9) from each individual transplant patient, representing each of three kidney donor 
groups (LD, DCD, and AKI), were processed and those RNAs of sufficient quantity and quality were 
used for gene expression analysis (Table 2).   
Total RNA was isolated from peripheral blood in a QIAcube robotic workstation using regents 
and protocols recommended by the manufacturer (PreAnalytix; Qiagen, Valencia, CA). Total RNA was 
evaluated for quantity (Nanodrop spectrophotometer) and quality (Agilent Bioanalyzer). Labeled cDNA 
derived from total RNA samples (RIN ≥ 7) was hybridized to whole-genome microarrays (HumanHT-
12 v4 Expression BeadChip; Illumina Inc.) using protocols recommended by the manufacturer. 
Annals of Surgery  February 21, 2018 
Following hybridization, washing, and scanning, data were extracted from scanned images using 
Genome Studio Software (Gene Expression module; Illumina Inc.) and processed for upload to gene 
expression analysis software.  
Statistical Analysis:  Following normalization (quantile) and log transformation of the raw data, 
unsupervised hierarchical clustering and analysis of variance (ANOVA) were performed, using Qlucore 
Omics Explorer (Qlucore, Lund, Sweden), to generate principal component analysis (PCA) plots and 
heat maps. 
Gene ontology and pathway analyses were performed by evaluating lists of differentially-
expressed transcripts in Ingenuity Pathway Analysis software (IPA, Qiagen). 
 
RESULTS 
Gene expression data were generated from peripheral blood samples taken at multiple times from 
each of 15 KT patients representing three donor kidney types: LD, AKI and DCD (Table 2). The 
majority (9/15) of the KT patients were Caucasian, 4 were African-American, and 2 were “other”, with a 
nearly equal number of males and females (8M:7F). The total number of blood samples processed was 
100. Following quality check, a total of 91 (28 LD, 31 AKI, and 32 DCD samples) were determined to 
be suitable for microarray analysis (Table 2).  
Initially we performed a comparative analysis of longitudinal peripheral blood gene expression 
(using all sample data) between recipients of LD grafts versus those with AKI/DCD grafts. This was 
accomplished using maSigPro, a statistical procedure specifically designed to identify genes that show 
different gene expression profiles across groups in time-course experiments[14]. The analysis revealed 
two significant gene clusters (p < 0.01), representing a total of 141 genes that show a different 
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expression profile between AKI/DCD and LD samples (Figure 2). Within the first two weeks post-
transplant there appear to be several small individual groups of transcripts that show differential 
expression between the LD and AKI/DCD groups (Figure 2; highlighted in blue boxes). Although the 
number of samples at these time points does not provide sufficient power to draw meaningful 
conclusions, the transcripts populating these mini-clusters may warrant further investigation if 
confirmed in a larger sample. 
The 77 transcripts that comprise cluster 1, most of which are downregulated over time compared 
to day 0, show a significant over-representation of genes in several key biological pathways including 
mTOR signaling (p=3.98E-05), Granzyme B Signaling (p=1.13E-03), and Th1 and Th2 Activation 
Pathway (p=2.73E-03) (Table 3). Immunological Disease (p=1.25E-02 - 3.76E-05) is the top diseases 
and disorders category over-represented in this cluster. 
The second cluster of differentially-expressed genes (N=64; mostly upregulated) in the 
comparison between AKI/DCD and LD are significantly over-represented in Toll-like Receptor 
Signaling (p=6.61E-05), Adrenergic signaling (p=1.12E-04), and fMLP Signaling in neutrophils 
(p=4.24E-04) pathways (Table 3). The most significant diseases and disorders category over-represented 
in the set of transcripts is Inflammatory Response (p=8.54E-03 –1.41E-06).    
The functional clustering of the 141 genes using PANTHER (http://pantherdb.org) identifies 
numerous relevant pathways. Of particular interest is the Wnt/beta catenin signaling pathway, known to 
play a positive role in the control of T-cell development, cell proliferation rate and differentiation. Three 
genes - transforming growth factor beta receptor type 3 (TGFBR3), gamma-secretase subunit (APH1B) 
and beta catenin (CTNNB1) - involved in Wnt/beta catenin signaling and in its immunomodulatory role 
were found to be altered in AKI/DCD patients compared to LD.  
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The 141 transcripts that are differentially expressed in the longitudinal comparison between LD 
and AKI/DCD include genes found to be different in: (1) LD vs AKI only (N=65) and, (2) LD vs DCD 
only (N=63). In the comparison of LD vs AKI + DCD (i.e. differentially expressed in both DGF groups) 
11 transcripts were identified: LPCAT2, MAL, DDX52, LMNB1, CYP1B1-AS1, RHOC, ID2, 
KLHDC4, GNG10 and GNl1 (Table 4).   
Next we performed gene expression analysis for each of the three donor types (LD, AKI and 
DCD) individually to determine if there were observable time-dependent and graft type-dependent 
patterns of gene expression discernible in peripheral blood. Due to the paucity of usable data for samples 
collected in weeks 2 and 3, these analyses were confined to samples from the early times points (day 0-
5) and the latest time point (day 28-30) only. For the heatmap depictions of the ANOVA results, the 
time points were arranged from day 0 to day 30 (Figure 3). We expected to see the greatest differences 
in blood gene expression between day 0 (before the kidney was transplanted to the recipient) and the 
first days following transplant, and then another a return to baseline at day 30 after the kidney function 
had stabilized in the new host.  
The pattern of gene expression in the LD group showed two distinct profiles (clusters) over time 
(Figure 3; left panels). In the first cluster, genes were upregulated at Day 0 and also at Day 1 and then 
expression trended downward in the majority of samples out to Day 30. In the second cluster, all of the 
transcripts had a large spike (increase) in expression on the first day following transplantation, and then 
trended downward from the 2nd day onward. The canonical pathways overrepresented in LD recipients 
(Table 5) are representative of cellular stress response (e.g. NF-κB signaling and p38 MAPK signaling) 
and a pro-inflammatory cellular response (e.g. role of macrophages, fibroblasts and endothelial cells in 
rheumatoid arthritis and LXR/RXR activation). 
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Differential gene expression over time in AKI graft recipients was uniformly high from Days 1-5 
following surgery compared to both pre- and 30 days post-transplantation (Figure 3; middle panels). The 
molecular pathways overrepresented in AKI recipient blood are involved in host defense (e.g. Fcγ 
receptor-mediated phagocytosis and actin cytoskeleton remodeling), leukocyte migration from blood to 
tissue during inflammation, and the production of nitric oxide and reactive oxygen species (Table 5). 
The longitudinal expression pattern gene expression in the blood of DCD recipients differs from 
patterns seen in both the LD and AKI recipients. A large number of genes are upregulated from the pre-
transplantation time point through most of the initial 5 days post-transplant. By Day 28-30 most of the 
transcripts’ expression levels have decreased significantly (Figure 3; right panels). Pathways that are 
upregulated throughout pre- and post-transplant (up to at least Day 5) time points are involved with 
innate and adaptive immunity including in B cell development, Th1 and Th2 pathway activation, antigen 
presentation, and apoptosis (e.g. the protein ubiquitination pathway; Table 5).               
 
DISCUSSION 
The study of DCD and AKI renal allograft recipients offers a truly unique platform for 
understanding how the acutely damaged kidney recovers (i.e. repairs and regenerates) in the recipient. 
Moreover, the use of human samples is arguably the most relevant approach, bypassing the need for 
animal studies that may not be able to reliably model the human response[28]. The most important 
finding from this study is significant, biologically relevant, and time-dependent gene expression changes 
in peripheral blood from KT patients receiving LD, AKI and DCD grafts in the initial day(s) following 
surgery and both the magnitude and duration of these changes is specific to the source of allograft. In 
general, once the donor graft has been implanted into the recipient there is an activation of the immune 
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system - counterbalanced by immunosuppressive therapy - and a resultant transient increase in the 
expression of apoptosis genes, genes involved in the immune response and in multiple cell signaling 
pathways. This is followed by a decrease, over time, in the expression of immune response genes, 
among others, until the recipient blood gene expression profile returns to baseline. The finding that gene 
expression remains elevated, at least through the first week following surgery, in those who have 
received AKI or DCD donor grafts suggest that there may be additional repair and regeneration 
activities occurring in these patients.    
The comparison of blood gene expression profiles between LD and AKI/DCD graft recipients 
revealed two clusters of differentially expressed genes. Among the 141 transcripts that populate these 
clusters, three genes involved in the Wnt-β-catenin signaling pathway (transforming growth factor beta 
receptor 3 (TGFBR3), catenin beta 1 (CTNNB1), and	 aph-1 homolog B, gamma-secretase subunit 
(APH1B)) were identified. These findings are of particular interest because this pathway is known to be 
involved both in kidney development[29, 30] and also in kidney repair and regeneration[31, 32]. Indeed, 
Lin and coworkers, using the kidney as a model, showed that the Wnt pathway ligand Wnt7b is 
produced by macrophages to stimulate repair and regeneration in the injured kidney[31]. Since Wnt7b is 
known to stimulate epithelial responses during kidney development, their data suggest that macrophages 
are able to rapidly invade injured tissue and reestablish a developmental program to facilitate repair and 
regeneration. Although the current pilot study did not specifically find a significantly increased 
expression of Wnt7b, there was a significant overrepresentation of genes in pathways involving 
macrophage activity during the post-transplant period (Table 5). Further analyses in a large patient 
cohort are required to validate genes within the Wnt-β-catenin signaling pathway as possible blood-
based markers predictive of tissue repair and regeneration. 
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The longitudinal analysis also resulted in the identification of eleven genes that were 
differentially expressed in both DCD and AKI samples compared to LD. These transcripts may 
represent the most biologically relevant gene targets differentiating the two groups and warrant further 
investigation. Among them, MAL, a T cell differentiation protein was previously described among the 
most relevant modulated genes in peripheral blood of immunosuppressive drug treated patients[33]. In 
fact, the differential expression in AKI/DCD vs LD patients may underlie a differential drug response 
and inflammatory activation of these patient populations and may possibly represent useful a prognostic 
marker.  
Traditionally, kidney biopsies have been used for gene expression profiling to gain insights 
regarding mechanisms of acute injury, as well to identify biological pathways involved in tolerance, 
immunosuppression, rejection and graft survival following KT. The primary limitation with this strategy 
is that, due to the invasive nature of procuring kidney biopsy tissue, it is not possible to do a multi time 
point investigation into the molecular events that are occurring within the initial recovery period (i.e. 
within the first 30 days). Profiling gene expression in peripheral blood offers a viable alternative 
strategy. In fact, in a recent study that performed a parallel profiling of peripheral blood and biopsy 
tissue samples from three groups of KT patients ([1] stable transplant, [2] subclinical acute rejection, 
and [3] clinical acute rejection) the authors report the equivalent predictive performance of the two 
analyses (blood and biopsy), so supporting the relevance of the results obtained in peripheral blood for 
detection of tissue dysfunction[34]. They further showed that comparisons between microarray and 
RNA sequencing signatures demonstrated a strong correlation between the blood and biopsy 
compartments regardless of the platform used.  
While the data generated in this pilot study are suggestive of important gene expression 
differences, over time, revealed in peripheral blood of patients who have undergone KT, there are 
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several limitations that must be noted. First, the original study goal was to generate gene expression 
profiles in a total of 10-12 blood samples per KT patient, covering the entire first 30 days post-
transplant, however this was not possible due to: (1) missing samples for some of the time points and, 
(2) samples for which the RNA quality was inadequate for further analysis. Although the number of 
samples in the 2nd and 3rd weeks post-transplant was uneven across individual sample sets and across 
groups, all data collected for all time points (Table 2) were used for the comparison of longitudinal gene 
expression differences between LD and AKI/DCD samples (Figure 2). And in the evaluation of gene 
expression profiles for each individual donor graft type, only samples from the first week (Day 0-6) and 
the final time point (Day 28-30) were used (Figure 3). This was done to maximize the power to detect 
relevant genes and biological pathways that are impacted in the critical time following KT. A more 
comprehensive understanding of genes and pathways involved in kidney repair and regeneration will 
need to include analysis of a more complete set of samples collected across all time points from Day 0 to 
30.  
Another limitation with this study was the inability to adequately match samples both within and 
between groups. The most obvious example is the fact that nearly all of the recipients of DCD grafts 
were African American whereas most of the other patients were Caucasian. Ethnicity can impact gene 
expression analysis and may explain at least some of the unusual pattern seen in the heatmap for gene 
expression in DCD samples (Figure 3; right panels). 
Finally, using peripheral blood gene expression analysis to derive mechanistic insight regarding 
processes occurring elsewhere in the body (e.g. the kidney) is not optimal. Serial kidney biopsies, taken 
in the days following KT, would likely yield the most relevant information regarding processes that 
underlie tissue repair and regeneration however, as noted earlier, this is not practical. For this reason, 
profiling of peripheral blood has become the method of choice and there is at least some encouraging 
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evidence that this approach can yield results similar to those achieved by profiling the target tissue, at 
least where the kidney is concerned[34].          
In conclusion, our data show that the pattern, magnitude, and duration of gene expression 
changes following KT are donor graft specific and provide information regarding molecular pathways 
and specific transcripts that are involved in the host response following this type of surgery. These 
results provide further evidence that measuring gene expression in an easily accessible surrogate tissue 
(whole blood) represents a convenient and biologically relevant approach. This has important 
implications for understanding the molecular mechanisms occurring in the host relative to the organ 
quality and to the consequent immunological activation. Additional analyses, involving increased 
sample numbers (number of patients and blood collection points), will be needed to validate candidate 
genes that underlie tissue repair and regeneration in patients receiving DCD and AKI kidney grafts. The 
discovery and understanding of the molecular pathways underlying successful kidney adaptive repair 
after damage will provide a unique opportunity to design targeted molecular- or cell-based therapies to 
accelerate the induction of repair and regeneration mechanisms in damaged kidneys. Such therapies 
would be broadly applicable across a myriad of clinical settings characterized by an acute or chronic 
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